BlackRock’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-133,256
| Closed | -$93.1K | – | 5665 |
|
|
2023
Q1 | $93.1K | Sell |
133,256
-3,044
| -2% | -$2.8K | ﹤0.01% | 4973 |
|
|
2022
Q4 | $123K | Sell |
136,300
-15,880
| -10% | -$46K | ﹤0.01% | 4979 |
|
|
2022
Q3 | $913K | Buy |
152,180
+14,940
| +11% | +$84.7K | ﹤0.01% | 4511 |
|
|
2022
Q2 | $568K | Buy |
137,240
+3,109
| +2% | +$11K | ﹤0.01% | 4735 |
|
|
2022
Q1 | $509K | Sell |
134,131
-17,122
| -11% | -$77.2K | ﹤0.01% | 4866 |
|
|
2021
Q4 | $681K | Buy |
151,253
+547
| +0.4% | +$2.78K | ﹤0.01% | 4784 |
|
|
2021
Q3 | $702K | Buy |
150,706
+25,332
| +20% | +$134K | ﹤0.01% | 4665 |
|
|
2021
Q2 | $884K | Sell |
125,374
-458,145
| -79% | -$2.47M | ﹤0.01% | 4554 |
|
|
2021
Q1 | $3.45M | Buy |
583,519
+11,004
| +2% | +$66.7K | ﹤0.01% | 4098 |
|
|
2020
Q4 | $2.64M | Buy |
572,515
+26,396
| +5% | +$114K | ﹤0.01% | 3953 |
|
|
2020
Q3 | $2.12M | Sell |
546,119
-5,247
| -1% | -$105K | ﹤0.01% | 3886 |
|
|
2020
Q2 | $15.9M | Buy |
551,366
+337,754
| +158% | +$7.82M | ﹤0.01% | 2919 |
|
|
2020
Q1 | $4.6M | Buy |
213,612
+50,079
| +31% | +$1.14M | ﹤0.01% | 3392 |
|
|
2019
Q4 | $3.22M | Buy |
163,533
+103,563
| +173% | +$1.47M | ﹤0.01% | 3633 |
|
|
2019
Q3 | $900K | Buy |
+59,970
| New | +$930K | ﹤0.01% | 4018 |
|
BlackRock's STSA Position: Q2 2023 in Review
BlackRock sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 133,256 shares — an estimated $93.1K sold.
BlackRock first reported a position in STSA in Q3 2019 and held it in 15 quarters. The position peaked at $15.9M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- BlackRock reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 133,256 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $93.1K.
- BlackRock first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- BlackRock's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $15.9M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.